Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Trends in Pharmacological Sciences, 11/06/09
Yazbeck R et al. – Dipeptidyl peptidase (DPP)–4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T–cell proliferation and cytokine production, leading to their investigation in numerous pre–clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4–specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non–specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease.
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Sponsor
Article Search
Sponsor